SCHEMBL490241

SCHEMBL490241

C[C@@]1(C(=O)O)Cc2sc(-c3ccc(C(=O)N4CCOCC4)cc3)cc2[C@@H]1c1cccc(F)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 4/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ABL1 P00519 2/20 0.40
BCR P11274 2/20 0.40
TRPM8 Q7Z2W7 1/20 0.39
HPGD P15428 3/20 0.38
TP53 P04637 1/20 0.37
HTT P42858 1/20 0.37
APC P25054 2/20 0.37
PARP10 Q53GL7 1/20 0.37
ERN1 O75460 1/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
SCD5 Q86SK9 1/20 0.36
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10169821 1.00 RIPK1 (0.41) RIPK1ALDH1A1KDM4EABL1BCR
SCHEMBL490240 1.00 RIPK1 (0.41) RIPK1ALDH1A1KDM4EABL1BCR
SCHEMBL490433 0.92 HPGD (0.43) ALDH1A1HPGDTP53HTTAPC
SCHEMBL490432 0.92 HPGD (0.43) ALDH1A1HPGDTP53HTTAPC
SCHEMBL10169814 0.92 HPGD (0.43) ALDH1A1HPGDTP53HTTAPC
SCHEMBL490249 0.84 NR3C1 (0.46) RIPK1ALDH1A1ABL1BCRTRPM8
SCHEMBL10169828 0.84 NR3C1 (0.46) RIPK1ALDH1A1ABL1BCRTRPM8
SCHEMBL10211129 0.77 MAPK13 (0.36) RIPK1ALDH1A1KDM4EHPGDTP53
SCHEMBL13575451 0.76 MAPK13 (0.36) ALDH1A1KDM4EHPGDTP53HTT
SCHEMBL10169820 0.75 HTR7 (0.34) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106046-B2 Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-31 US disclosed
EP-2334671-A1 CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF Bristol-Myers Squibb Company (US) 2011-06-22 EP disclosed
US-20110105495-A1 CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
WO-2009158380-A1 CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105495-A1 CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFKB2, NFKB1, NFRKB RIPK1 581/4885ALDH1A1 2550/4885KDM4E 2394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.